BridgeBio Oncology Therapeutics, Inc.
Close on Oct 19, 2026
- Market cap
- $228.15M
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Next report expected Nov 11, 2026, after market close (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 11, 2026 | After market close | – | – | – |
| Q1 FY2026 Ended Mar 31, 2026 | May 12, 2026 | After market close | – | $-526.11 | – |
| Q4 FY2025 Ended Dec 31, 2025 | Mar 5, 2026 | After market close | – | $-0.49 | – |
| Q3 FY2025 Ended Sep 30, 2025 | Nov 12, 2025 | After market close | – | $-1.03 | – |
Press releases
Announcements BridgeBio Oncology Therapeutics filed with the SEC
Corporate Update September 2026 BBOT Next-Generation RAS-Pathway
Other events · EX-99.2 to Form 8-K
BBOT Reports Second Quarter 2026 Financial Results and Update on Corporate Progress
Results of operations · EX-99.1 to Form 8-K
BBOT Reports First Quarter 2026 Financial Results and Update on Corporate Progress
Results of operations · EX-99.1 to Form 8-K
BBOT Announces the Appointment of Pedro J. Beltran, PhD, as Chief Executive Officer, Idan Elmelech as
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
BBOT Reports Fourth Quarter and Full Year 2025 Financial Results and Update on Corporate Progress
Results of operations · EX-99.1 to Form 8-K
BBOT Announces New Clinical Data Advancing Its Portfolio of Three Innovative and Differentiated RAS and
Other events · EX-99.1 to Form 8-K
BBOT Reports Third Quarter 2025 Financial Results and Update on Corporate Progress
Results of operations · EX-99.1 to Form 8-K
THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS OF BBOT AS OF JUNE 30, 2025 AND FOR THE SIX MONTHS ENDED JUNE 30, 2025 AND 2024
Material agreement · Acquisition or disposition completed · Unregistered share sale · Auditor change · Executive or director change · Charter or bylaw amendment · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
THE UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION OF PUBCO AS OF AND FOR THE SIX MONTHS ENDED JUNE 30, 2025 AND FOR THE YEAR ENDED DECEMBER 31, 2024
Material agreement · Acquisition or disposition completed · Unregistered share sale · Auditor change · Executive or director change · Charter or bylaw amendment · Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
MANAGEMENT'S DISCUSSION AND ANALYSIS OF THE FINANCIAL CONDITION AND RESULTS OF OPERATIONS OF BBOT FOR THE SIX MONTHS ENDED JUNE 30, 2025 AND 2024
Material agreement · Acquisition or disposition completed · Unregistered share sale · Auditor change · Executive or director change · Charter or bylaw amendment · Regulation FD disclosure · Other events · EX-99.3 to Form 8-K
PRESS RELEASE, DATED AUGUST 6, 2025
Regulation FD disclosure · EX-99.1 to Form 8-K
PRESS RELEASE, DATED JULY 11, 2025
Regulation FD disclosure · EX-99.1 to Form 8-K
PRESS RELEASE, DATED FEBRUARY 28, 2025
Regulation FD disclosure · EX-99.1 to Form 8-K
INVESTOR PRESENTATION, DATED FEBRUARY 2025
Regulation FD disclosure · EX-99.2 to Form 8-K
AUDITED BALANCE SHEET AS OF FEBRUARY 13, 2024
Other events · EX-99.1 to Form 8-K
PRESS RELEASE, DATED FEBRUARY 9, 2024
Material agreement · Unregistered share sale · Executive or director change · Charter or bylaw amendment · Other events · EX-99.1 to Form 8-K
PRESS RELEASE, DATED FEBRUARY 14, 2024.
Material agreement · Unregistered share sale · Executive or director change · Charter or bylaw amendment · Other events · EX-99.2 to Form 8-K